Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Phathom Pharmaceuticals, Inc. - Common Stock
(NQ:
PHAT
)
5.770
+0.150 (+2.67%)
Streaming Delayed Price
Updated: 4:00 PM EST, Feb 14, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Phathom Pharmaceuticals, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
Next >
$14M Bet On This Technology Stock? Check Out These 4 Stocks Insiders Are Buying
February 15, 2023
Although US stocks closed mixed on Tuesday, there were a few notable insider trades.
Via
Benzinga
GLOBALLY RECOGNIZED ROSEN LAW FIRM Encourages Phathom Pharmaceuticals, Inc. Investors to Inquire About Securities Class Action Investigation – PHAT
February 14, 2023
From
The Rosen Law Firm PA
Via
GlobeNewswire
One Analyst Is Bullish While Another Sees Overhang On Phathom Pharma Stock After Two Rejection Letters
February 10, 2023
FDA issued two Complete Response Letters to Phathom Pharmaceuticals Inc's (NASDAQ: PHAT) vonoprazan marketing application for the erosive esophagitis (EE) indication and H. pylori (HP) indication...
Via
Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
February 10, 2023
Via
Benzinga
Where Phathom Pharmaceuticals Stands With Analysts
February 10, 2023
Via
Benzinga
Phathom Pharma Shares Fall After Formal FDA Request For Vonoprazan Data
February 10, 2023
Via
Benzinga
BMO Capital Maintains Outperform Rating for Phathom Pharmaceuticals: Here's What You Need To Know
January 04, 2023
Via
Benzinga
Why Hempacco Are Trading Lower By 58%? Here Are Other Stocks Moving In Friday's Mid-Day Session
February 10, 2023
Gainers SeqLL Inc. (NASDAQ: SQL) shares jumped 120% to $1.85 after dropping around 39% on Thursday. SeqLL recently announced the establishment of a two-year Cooperative Research and Development...
Via
Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
February 10, 2023
Via
Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
February 09, 2023
Via
Benzinga
Phathom Pharmaceuticals Provides Regulatory Updates
February 09, 2023
From
Phathom Pharmaceuticals
Via
GlobeNewswire
TOP RANKED ROSEN LAW FIRM Encourages Phathom Pharmaceuticals, Inc. Investors to Inquire About Securities Class Action Investigation – PHAT
February 09, 2023
From
The Rosen Law Firm PA
Via
GlobeNewswire
Bragar Eagel & Squire, P.C. Is Investigating Credit Acceptance, and Phathom and Encourages Investors to Contact the Firm
February 03, 2023
From
Bragar Eagel & Squire
Via
GlobeNewswire
Why Shares of Phathom Pharmaceutical Jumped This Week
January 28, 2023
Investors are reading between the lines to see if the company is fixing its problems regarding its lead therapy.
Via
The Motley Fool
Seagate, Boot Barn, Tesla And Other Big Stocks Moving Higher On Thursday
January 26, 2023
U.S. stocks traded higher, with the Nasdaq Composite gaining over 100 points on Thursday. Here are some big stocks recording gains in today’s session.
Via
Benzinga
Bragar Eagel & Squire, P.C. Is Investigating Phathom, Super Micro, and Fate and Encourages Investors to Contact the Firm
January 18, 2023
From
Bragar Eagel & Squire
Via
GlobeNewswire
PHATHOM ALERT: Bragar Eagel & Squire, P.C. is Investigating Phathom Pharmaceuticals, Inc. on Behalf of Phathom Stockholders and Encourages Investors to Contact the Firm
January 11, 2023
From
Bragar Eagel & Squire
Via
GlobeNewswire
Why CinCor Pharma Shares Are Trading Higher By 140%; Here Are 20 Stocks Moving Premarket
January 09, 2023
Gainers CinCor Pharma, Inc. (NASDAQ: CINC) rose 140.2% to $28.30 in pre-market trading after AstraZeneca announced plans to buy the company for up to $1.8 billion.
Via
Benzinga
Phathom Pharmaceuticals Announces Positive Topline Results from Phase 3 PHALCON-NERD-301 Trial Evaluating Daily Dosing of Vonoprazan for Symptomatic Non-Erosive Gastroesophageal Reflux Disease (NERD)
January 08, 2023
From
Phathom Pharmaceuticals
Via
GlobeNewswire
Dow Gains 150 Points After Fed Minutes
January 04, 2023
U.S. stocks traded higher toward the end of trading, following the release of minutes from the FOMC meeting.
Via
Benzinga
Why Enovix Shares Are Trading Lower By 43%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
January 04, 2023
Gainers Vivos Therapeutics, Inc. (NASDAQ: VVOS) shares surged 204% to $2.25 after the company announced it received FDA 510(k) clearance for its DNA oral appliance for the treatment of obstructive...
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
January 04, 2023
Via
Benzinga
Nasdaq Rises Over 100 Points; Crude Oil Drops Sharply
January 04, 2023
U.S. stocks extended gains midway through trading, with the Dow Jones gaining around 250 points on Wednesday ahead of the release of minutes from the Fed's meeting.
Via
Benzinga
US Stocks Open Higher Ahead Of Fed Minutes; Dow Rises 100 Points
January 04, 2023
U.S. stocks traded higher this morning, with the Dow Jones gaining over 100 points on Wednesday.
Via
Benzinga
FDA Issues No Action Notice For Phathom Pharma's Investigational Candidate, Shares Plunge
January 04, 2023
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
January 04, 2023
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
January 04, 2023
We're starting off the day with a breakdown of the biggest pre-market stock movers traders need to know about on Wednesday!
Via
InvestorPlace
Vera Therapeutics, Phathom Pharmaceuticals And Some Other Big Stocks Moving Lower In Today's Pre-Market Session
January 04, 2023
U.S. stock futures traded higher this morning. Here are some big stocks recording losses in today’s pre-market trading session.
Via
Benzinga
Phathom Pharmaceuticals Provides Update on New Drug Application Review of Vonoprazan for Erosive Esophagitis
January 03, 2023
From
Phathom Pharmaceuticals
Via
GlobeNewswire
Biogen's 2nd Alzheimer's Antibody, BeiGene's Cancer Drug Label Expansion, Adcom Test For Regeneron And More: January PDUFA Catalysts For Biotech Investors
December 27, 2022
Biopharma stocks were not immune to the broader market downturn seen for much of 2022.
Via
Benzinga
< Previous
1
2
3
4
5
6
7
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.